and interventions based on individual's cumulative risk profile are likely to maximize the benefit of the interventions. 8, 10 Several multivariable prediction models have been developed for predicting incident heart failure, although they have not been used in healthcare settings. 15 A number of the existing models were developed based on younger patients where incidence of the disease is low, [15] [16] [17] while others were undertaken to evaluate a single biomarker. 18, 19 Possible misclassification of heart failure events is also likely in many of the studies where heart failure was defined either as a hospitalization for heart failure, or cause of death coding. 9, 15, 17 Several heart failure models also consist of imaging data as a predictor for heart failure, which may increase performance of the model but could also limit its application in the primary and community care settings. 9, 20, 21 Heart failure prevention guidelines advocate for the early detection and slowing disease progression using pharmacological and nonpharmacological strategies including physical activity and risk factor modification. 22, 23 Heart failure risk prediction models consisting of routinely collected measurements could facilitate cost-effective prevention of heart failure and improve patient outcomes.
This study aims to develop and validate a risk prediction model for predicting 10-year risk of heart failure diagnosis in elderly hypertensive participants enrolled in the Second Australian National Blood Pressure Study (ANBP2). The participants were aged 65-84 years and hypertensive at study entry.
METHODS

Study population
The ANBP2 clinical trial was a prospective randomized, open-label study with blinded assessment of end-points conducted in 1,594 Australian general practices between March 1995 and September 2001. 24 The study compared the difference in major adverse cardiovascular outcomes between hypertensive patients randomized to either an angiotensinconverting enzyme inhibitor-based regimen or a thiazide diuretic-based regimen. 24 The study included 6,083 hypertensive participants aged 65 to 84 years at study entry, of whom 62% had previously taken antihypertensive medication. The majority, 95% were White and relatively healthy (only 8% had a previous coronary heart disease event, 5% a previous cerebrovascular event, and 7% had diabetes mellitus at study entry). 24, 25 The study design and baseline characteristics have been published elsewhere. 24, 26 Study inclusion criteria included an average untreated systolic blood pressure (SBP) at the 2 study entry visits of ≥160 mm Hg or an average diastolic BP of ≥90 mm Hg (if SBP was ≥140 mm Hg). 26, 27 Patients with any cardiovascular morbidity, including heart failure, within the 6 months prior to the study screening visit were excluded.
There was a median in-trial follow-up of 4.1 years (interquartile range = 3.9-4.6), and an additional median 6.7 years posttrial follow-up of consenting participants for long-term morbidity and mortality; hence, there was a total follow-up period of 10.8 years (interquartile range = 9.4-11.4). 4 
Measurement of risk factors
At entry into the ANBP2 study, BP measurements were taken at 2 office visits (with 3 readings on each occasion) at least 1 week apart by a study nurse using a standard mercury sphygmomanometer. Anthropometric and blood biochemistry measurements were derived from the existing medical record or, where this was unavailable for the preceding 12 months, measurements were taken during the screening phase of the study. Demographics, alcohol consumption (never, past, current), and cigarette smoking (never, past, current) were self-reported using a questionnaire. Diabetes mellitus and previous history of cardiovascular events were documented by the usual treating physician. 25 Visit-to-visit BP variation was computed as an average of absolute differences between BP readings of consecutive visits. Average on-treatment SBP and diastolic BP were calculated by the use of all post-randomization BP measurements to the last visit before the date of diagnosis of heart failure or the end of the clinical trial follow-up in those patients without heart failure.
Study outcome
For all end-point events that occurred during the ANBP2 clinical trial, a treating physician contacted a study nurse who then documented all relevant information on the event, including information derived from any relevant hospital admission. A review of the patient medical record was also made regularly by study nurses to identify and document additional events. All events were adjudicated by an endpoint committee blinded to treatment allocation. 28 In the posttrial follow-up, diagnosis of heart failure was reported by their treating medical practitioner. In making the diagnosis of heart failure, clinicians may have also reported the results of clinical investigations such as echocardiography, ECG, and X-ray. In addition, those participants without reported heart failure diagnosis (by their treating clinician) but who were identified as having heart failure as a cause of death in the National Death Index (NDI) were also included. The International Classifications of Diseases 10 th Revision (ICD-10) codes were used to extract deaths related to heart failure mentioned in any diagnostic position in the NDI list. The definition of heart failure in the posttrial follow-up has previously been described. 4 
STATISTICAL ANALYSIS
Development of the predictive model
Both the in-trial and posttrial follow-up data were used to develop the model. All participants (6,083) were free of heart failure at baseline and were therefore included in the analysis. Variables with P ≤0.2 in the univariate Cox-regression were considered as candidate predictors for the multivariable models. 9 All candidate predictors were evaluated for any interaction with age and gender.
A parsimonious model was developed based up on a 1,000 bootstrap resamples on the original data using multivariable Cox regression. 29 For each candidate predictor, the proportion of bootstrap samples in which that variable was identified as a significant independent predictor of the risk of heart failure (P ≤ 0.05) was determined. 30 Within each bootstrap sample, backward elimination was used to develop a parsimonious predictive model.
Four candidate models consisting of those variables identified as significant predictors (P < 0.05) in at least 90%, 80%, 70%, and 60% of the 1,000 bootstrap resampling were developed. 27, 29 The 4 models were fitted to the original data, to select a final model that has the lowest Akaike Information Criterion and Bayesian Information Criterion, and highest C-statistic. The predictive performance of the models (C-statistics) was determined using the Somers' D approach for censored data. 31 The linearity of the association between continuous predictors and incident heart failure was also assessed. 30 After fitting the full model, we combined categories of variables that were similar with comparable hazard ratios where possible. For example, presence of cardiovascular disease (CVD) at baseline and during the trial (prior to heart failure diagnosis) were combined since the hazard ratios for both were similar and the 95% confidence intervals overlapped. The final model was evaluated for proportionality assumption and multicollinearity.
Internal validation
The final model was internally validated using bootstrapping (1,000 replications) according to the 9 steps described by Harrell et al. 32 Optimism in performance of the model, due to over fitting, was estimated as the average of the difference in performance of the model in the bootstrap sample and original dataset (C-statistics bootstrap sample − C-statistics original dataset ) for models derived from the 1,000 bootstrap replications. 9, 32, 33 The optimism was then subtracted from the original performance measure (C-statistic of the original model) to provide the optimism-corrected C-statistics of the final model. 9, 33 Shrinkage factor was estimated as the percentage of the difference between C-statistics of the original model and the optimism-corrected C-statistics. Coefficients from the multivariable Cox-regression were also multiplied by the shrinkage factor to recalibrate the final model allowing for more reliable predictions. 33 Calibration of the model was evaluated by plotting the predicted vs. observed deciles of predicted risk, and using goodness-of-fit test for Coxregression analogous to the Hosmer-Lemeshow goodnessof-fit test. 34 
RESULTS
The derivation cohort included 6,083 subjects randomized to angiotensin-converting enzyme inhibitor (3,044 subjects) or thiazide diuretic (3,039 subjects) -based treatment. The majority (62%) were receiving antihypertensive drug treatment prior to entry in to the study ( Table 1 ). The mean age (±SD) at randomization was 72 ± 5 years. Three-quarters of the participants were physically active, and 22% were obese (body mass index > 30 kg/m 2 ).
There were 319 cases of heart failure (145 during the intrial and 174 during the posttrial period) diagnosed over a median follow-up of 10.8 years. Compared with those who did not develop heart failure, those who developed heart failure were slightly older and had higher prevalence of CVD (17% vs. 12%) and diabetes (13% vs. 7%) at baseline. Table 1 summarizes the baseline and in-study characteristics.
Predictors of incident heart failure
We identified 319 incident cases of heart failure arising from 59,581 person-years of observation, giving a rate of 5.4 per 1,000 person-years. Of the 21 baseline and in-study variables listed, 16 variables with a P ≤ 0.20 in Cox's univariable (18) Number (%), mean ± SD. Abbreviations: ACE-I, angiotensinconverting enzyme inhibitor; CVD, cardiovascular disease (includes myocardial infarction, stroke, and acute coronary events), SBP, systolic BP; DBP, diastolic BP. regression analysis were considered as a potential risk factors for the multivariable model (Table 2 ). In the multivariable Cox-regression 4 candidate models consisting of variables identified as significant predictors (P < 0.05) in at least 90%, 80%, 70%, and 60% of the 1,000 bootstrap samples were developed.
The final model included age (in years), male sex, obesity (body mass index > 30 kg/m 2 ), pre-existing CVD, average visit-to-visit SBP variability (in mm Hg) and past and, current smoking (C-statistic = 0.719, Akaike Information Criterion = 5,185.26, Bayesian Information Criterion = 5,225.541) ( Table 3 ). All risk factors included in the final model were associated with increased risk of heart failure.
The model has C-statistics of 0.719 (95% CI: 0.705-0.748) in the derivation cohort, and 0.716 (95% CI: 0.701-0.731) after internal validation (optimism corrected). The goodness-of-fit test demonstrate that model has an overall good calibration (χ 2 = 1.78, P = 0.94). The Kaplan-Meier plot of observed vs. predicted heart failure free survival probabilities in 4 risk groups based on a prognostic index nearly to coincide supporting a good calibration of the model (Figure 1) . Presentation of the model, accompanied by an example of 10-year heart failure risk prediction is given in Appendix 1 (Supplementary File S1) .
DISCUSSION
In the present study, we developed and internally validated a model for predicting the 10-year risk of developing incident heart failure in a large hypertensive population aged over 65 years. The model has a good discrimination, calibration, and stability. It consists of variables which are readily accessible in primary and community care settings. Abbreviations: BC, bias corrected after 1,000 bootstrap resamples; BP, blood pressure; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; SBP, systolic blood pressure; SE, standard error of β.
a At baseline or during follow-up. Heart failure is mainly a disease of the elderly, and as the population ages the prevention of heart failure is becoming a healthcare priority worldwide. 11 Due to the morbidity and mortality of heart failure, its prevention is important in this age group. This largely depends on identification and management of risk factors before the development of clinically overt heart failure. 8, 10, 11, 22 Those with heart failure usually have multiple medical conditions prior to progression into overt heart failure, which can be used to develop multifactorial risk predictions. 11, 33 The prediction model developed in the present study consists of age, obesity, male sex, pre-exiting CVD, average visit-to-visit SBP variation, current and past smoking. All predictors included in the multivariable model were associated with increased risk of heart failure. Age, smoking, and coronary heart disease have been identified as predictors of the risk of heart failure in previous models and their effect on the risk of heart failure is well known. 9, 15, 35 Our model included average visit-to-visit SBP variation during followup rather than baseline SBP which has been included in existing heart failure models. 9, 15 However, the superiority of SBP variation over a baseline SBP in predicting CVD is well established including in a large meta-analysis providing support for this parameter in our model. 36 Also consistent with the findings of previous studies, incident heart failure was predicted by male gender. 3, 5, 17 This effect persisted after the association was adjusted for smoking and pre-existing CVD, which were more prevalent in men than in women. Obesity was associated with increased risk of heart failure during the follow-up. However, overweight (body mass index 25-30 kg/m 2 ) had no significant effect on the onset of incident heart failure. This trend is consistent with findings from the Framingham Heart Study and other studies in that it is the most overweight individuals who are at particular risk of heart failure. 5, 37 Overall, the predictive model had a very good discrimination and calibration. Furthermore, using internal validation in 1,000 bootstrap resamples the percentage of fit due to noise was 0.5%, suggesting a stable performance for application in an external dataset. 34 The optimism-corrected discrimination performance (C-statistics = 0.716) in the present model is similar to the C-statistics reported for many heart failure prediction models reported in a recent review. 9, 17 Our model addresses limitations of previous heart failure risk prediction models. First, it provides a good long-term (more than 10 years) estimate of the risk of incident heart failure in the elderly. Existing heart failure risk prediction models are either limited to predicting a short-term risk of heart failure 9, 21, 22 or to younger patients. [15] [16] [17] Long-term prediction (10 years) for risk estimation is widely adopted as it helps to identify at risk patients who can benefit from long-term interventions, which is the case in general for the prevention of CVD. 38 Unlike previous models which require imaging data, our model consists of variables which can easily be accessed from patients' routine medical record in primary care. 20, 21 Thus, it can help early detection of high-risk subjects who require in-depth screening, if integrated into the existing medical record system. 15 The present study has several strengths. It was conducted in an elderly population, who bear the largest burden of heart failure, but are usually excluded from many studies. 1 The study also utilized data from a large cohort of elderly hypertensive participants treated with the contemporary antihypertensive medications. Participants were followed for more than a decade, which is usually sufficient to observe the long-term development of heart failure. The study was reported in accordance with the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement for prediction studies. 39 This study has some limitations. First, the prediction model was not externally validated, thus future research should include evaluation of the transportability of the model to other settings and populations. As the majority of participants were Caucasian, validation of the model in other racially diverse cohorts is recommended prior to external application.
The clinical features such as left ventricular hypertrophy and ejection fraction which are potentially important for predicting and describing HF were not collected. The model was based on follow-up of participants enrolled in a randomized clinical trial of antihypertensive treatment, and thus may not be generalizable to the general population of the same age or untreated hypertensive patients. 40 In addition, some patients (96/319) were identified from the NDI report based on ICD coding. The ICD coding instructions does not instruct coding for heart failure as an underlying cause of death, and therefore, misclassification of heart failure events may have occurred. To minimize underreporting due to coding, heart failure mentioned in any diagnostic position in the NDI list was extracted.
In conclusion, the multivariable model developed in the present study has a good performance in predicting longterm incident heart failure in the elderly. It consists of variables routinely collected during follow-up of hypertensive population in primary care and community settings. The model can be integrated in to electronic medical record systems to allow early detection of high-risk subjects who require closer follow-up and care. Its application for the prediction of heart failure needs to be studied in the community setting to determine its utility for improving patient management and disease prevention.
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